Table 2 Changes in estimated glomerular filtration rate (eGFR), CD4+ T cell count (CD4), and lipids at 24 and 48 weeks after starting darunavir/cobicistat

eGFR mL/min

 T0

94.2

20.3

96.3

23.6

 T1

90.2

19.0

88.7

21.7

 T2

86.7

17.7

87.7

18.6

T1-T0 (mean, SE)

− 4.6*

1.8

− 7.6*

1.3

0.19

T2-T0 (mean, SE)

− 7.6*

1.9

− 8.5*

1.4

0.71

CD4 cells/mm³

 T0

625.2

381.0

580.6

342.9

 T1

653.3

309.2

641.0

364.4

 T2

712.6

326.0

664.1

365.0

T1-T0 (mean, SE)

18.5

30.5

60.8*

15.6

0.22

T2-T0 (mean, SE)

35.3

26.7

64.2*

19.1

0.38

HDL mg/dL

 T0

51.0

16.6

47.0

14.8

 T1

50.2

15.6

47.9

14.8

 T2

52.8

16.3

47.3

15.2

T1-T0 (mean, SE)

− 1.2

1.0

1.2

0.8

0.07

T2-T0 (mean, SE)

1.8

2.2

0.7

1.2

0.62

TC mg/dL

 T0

200.0

47.6

187.3

42.5

 T1

199.4

45.8

190.0

40.8

 T2

204.5

45.3

192.5

46.6

T1-T0 (mean, SE)

− 1.2

3.6

3.6

2.3

0.24

T2-T0 (mean, SE)

0.1

5.0

2.4

3.3

0.69

TG mg/dL

 T0 (median, IQR)

128

92–169

124

88–168

 T1 (median, IQR)

133

97–177

111

86–167

 T2 (median, IQR)

145

90–183

120

86–194

T1-T0 (mean, SE)

32.3

31.7

− 5.7

4.4

0.24

T2-T0 (mean, SE)

4.3

8.6

3.3

6.5

0.92

TC/HDL

 T0

4.20

1.34

4.27

1.37

 T1

4.26

1.39

4.25

1.38

 T2

4.11

1.21

4.31

1.29

T1-T0 (mean, SE)

0.07

0.08

− 0.05

0.08

0.31

T2-T0 (mean, SE)

− 0.13

0.14

− 0.05

0.09

0.62